Iqvia Holdings, Inc. · NYSE:IQV
Iqvia — IQVIA Life Sciences Innovation Forum 2022
10 slides from Iqvia's conference presentation, Sep 15, 2022
Slide 1: IQVIA Life Sciences Innovation Forum: Set-up Slides: Advancing Health System Sustainability
IQVIA Life Sciences Innovation Forum S e t - u p S l i d e s : Ad va n c i n g H e a l t h S ys t e m Sustainability September 15, 2022 Copyright © 2021 IQVIA. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States and various other countries.
Slide 2: Drug spending is a small portion of health spending and generally rising more slowly
Drug spending is a small portion of health spending and generally rising more slowly in all countries since 2000 Per Capita Drug (Hospital and Retail) and Health Spending in Real PPP 2020$, 2000-2018 US Japan Germany Ireland Bulgaria Spain Italy Cost per capita (Int.$) 12,000 12,000 10,000 10,000 10
Slide 3: Therapies are not consistently dispensed in the same venues
Therapies are not consistently dispensed in the same venues, with hospital share ranging from 0 to 100% in some cases Hospital Share of Audited Spending, Constant US$, 2020 Hospital share of audited spending 2020 UK, 98% IT, 100% ES, 100% KR, 99% IT, 100% ES, 100% UK, 95% KR, 94% UK, 77% 70.1% 70.4%
Slide 4: Drug spending share of healthcare has been converging around 15%
Drug spending share of healthcare has been converging around 15%, where greater variations existed previously Drug Spending % of Healthcare Spending in Real PPP 2020$, 2000-2018 Czech Republic Korea Bulgaria 30 Hungary Spain Japan 25 Germany Italy France 20 Croatia Ireland Average 15 Belgium Austral
Slide 5: Specialty medicines will represent about 45% of global spending in 2026
Specialty medicines will represent about 45% of global spending in 2026 and almost 60% of total spending in developed markets Specialty medicines share of spending Forecast 58% 48% 49% 45% 38% 44% 39% 35% 26% 26% 31% 22% 18% 15% 11% 11% 2011 2016 2021 2026 10 developed Other developed Pharmerging Gl
Slide 6: Significantly different drivers of growth across countries
There are significantly different drivers of growth across countries reflecting diverse systems, priorities and market dynamics Drivers of growth by product type in real local currency, 1996-2020 U.S. Japan Germany France Italy Spain 250 4,000 20 14 10 8 200 12 8 3,000 15 10 6 150 2,000 8 6 4 Growth
Slide 7: Spending has shifted between therapy classes based on continued innovation
Across eleven major markets, spending has shifted between therapy classes based on the continued flow of innovation Eleven country composition of drug real 2020$ drug spending by drug class, 1995-2020 100% All others Anti-bacterials 90% Dermatologics Anti-ulcerants 80% Cholesterol Onco support 70% G
Slide 8: Distribution of spending has shifted to different therapy areas over 25 years
Distribution of spending has shifted to focus on different therapy areas over 25 years with variations across the major countries Share of real 2020$ drug spending by drug class 1995 vs. 2020 Share of drug spending - 1995 Share of drug spending - 2020 11 countries U.S. U.S. JAPAN JAPAN GERMANY GERMA
Slide 9: Global market growth will return to pre-pandemic projections by 2025
Global market growth will return to pre-pandemic projections by 2025 despite year-to-year fluctuations Comparison of Current Outlook to Pre-COVID Outlook Constant Dollar Growth Forecast (Invoice) Key Events in the Outlook 12% 1 2020: -2.1% (~$27Bn) 10% Incremental COVID-related usage 3 for treatment
Slide 10: Day 4: Advancing Health System Sustainability
Day 4: Advancing Health System Sustainability Areas for discussion Overcoming Disparities How can the issues of disparities linked to race, ethnicity, gender, age and socio-economic conditions be addressed in a sustainable way that also balances population health needs with individual patient prefer
IQVIA Holdings — IQVIA Life Sciences Innovation Forum 2022 on 6ix